Objective To explore the clinical effect of Dienogest in the treatment of recurrent ovarian endometriotic cysts(OEM).Methods A total of 86 patients with recurrent OEM who were admitted to Weihai Maternal and Child Health Hospital from February 2022 to August 2023 were selected as the study objects.All the patients were divided into the study group(n=43)and the control group(n=43)by the random number table method.The control group received routine treatment,and the study group received the treatment with Dienogest.The cyst volume,hormone levels,ovarian reserve function,hemodynamics,and incidence of adverse reactions of the two groups were compared.Results After treatment,the cyst volume in both groups was decreased,and that of the study group was smaller than that of the control group(P<0.05).After treatment,the estradiol and follicle stimulating hormone levels in both groups were decreased,and the levels of the study group were lower than those of the control group(P<0.05).After treatment,the anti-Müllerian hormone levels in both groups were decreased,and the level of the study group was lower than that of the control group(P<0.05).After treatment,there was no statistically significant difference in antral follicle count between the two groups(P>0.05).After treatment,the ovarian arterial blood flow pulsation index and resistance index in both groups were decreased,and those of the study group were lower than those of the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Deinorgestrel for treatment of recurrent OEM can reduce cyst volume,improve hormone levels,ovarian reserve function,hemodynamics,and does not increase adverse reactions.
维普
万方数据